CANCER

The KRAS-BCAA-BCAT2 axis in PDAC development

Understanding the metabolic rewiring of pancreatic ductal adenocarcinoma is an emerging strategy for identifying cancer-associated liabilities and improving treatment. A new study now elucidates the function of the transaminase BCAT2 in the early stages of tumor development, providing insights that could stimulate novel therapeutic strategies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: KRAS mutation boosts BCAA metabolism, which promotes PanIN development.

References

  1. 1.

    Vander Heiden, M. G. & DeBerardinis, R. J. Cell 168, 657–669 (2017).

    Article  Google Scholar 

  2. 2.

    Maddocks, O. D. K. et al. Nature 544, 372–376 (2017).

    CAS  Article  Google Scholar 

  3. 3.

    Mayers, J. R. et al. Science 353, 1161–1165 (2016).

    CAS  Article  Google Scholar 

  4. 4.

    Li, J.T. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-019-0455-6 (2020).

  5. 5.

    Raffel, S. et al. Nature 551, 384–388 (2017).

    CAS  Article  Google Scholar 

  6. 6.

    Tönjes, M. et al. Nat. Med. 19, 901–908 (2013).

    Article  Google Scholar 

  7. 7.

    Dey, P. et al. Nature 542, 119–123 (2017).

    CAS  Article  Google Scholar 

  8. 8.

    Siegel, R. L., Miller, K. D. & Jemal, A. CA Cancer J. Clin. 67, 7–30 (2017).

    Article  Google Scholar 

  9. 9.

    Ananieva, E. A. & Wilkinson, A. C. Curr. Opin. Clin. Nutr. Metab. Care 21, 64–70 (2018).

    CAS  Article  Google Scholar 

  10. 10.

    Carrer, A. et al. Cancer Discov. 9, 416–435 (2019).

    Article  Google Scholar 

  11. 11.

    Goncalves, M. D., Hopkins, B. D. & Cantley, L. C. N. Engl. J. Med. 379, 2052–2062 (2018).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Oliver D. K. Maddocks.

Ethics declarations

Competing interests

O.D.K.M. contributed to the CRUK Cancer Research Technology’s filing of UK Patent Application no. 1609441.9, and is a founder and shareholder of Faeth Therapeutics.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Falcone, M., Maddocks, O.D.K. The KRAS-BCAA-BCAT2 axis in PDAC development. Nat Cell Biol 22, 139–140 (2020). https://doi.org/10.1038/s41556-020-0467-2

Download citation

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing